Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MGI Pharma Files Aquavan NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.

You may also be interested in...



FDA Rejects Eisai’s Aquavan Injection

Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.

FDA Rejects Eisai’s Aquavan Injection

Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.

Committee To Probe Dosing Of MGI's Aquavan

May 7 agenda will look into providers untrained in anesthesia, too.

Related Content

Topics

UsernamePublicRestriction

Register

PS066665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel